Luisa Mehr

Luisa Mehr

Auto-generated profile, based on publicly available information

Luisa Mehr

Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, Braunschweig 38124, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2026 in Journal of Natural Products
Verified
Journal Article
Open access
FFFranziska Fries
Franziska Fries
SWSebastian Walesch
Sebastian Walesch
RJRolf Jansen
Rolf Jansen
KPKristin von Peinen
Kristin von Peinen
LMLuisa Mehr
Luisa Mehr
JHJennifer Herrmann
Jennifer Herrmann
Antimicrobial resistance represents an escalating global health crisis, with drug-resistant infections predicted to cause up to 10 million deaths annually by 2050, underscoring the urgent need for novel antibiotics. Natural products play a crucial role in the discovery and development of antibiotics, with myxobacteria emerging as a particularly promising source due to their ability to produce structurally diverse and bioactive compounds. One prominent example of antibiotics from myxobacteria are the sorangicins, potent inhibitors of the bacterial RNA polymerase (RNAP). Here, we report the isolation of two unprecedented compounds, neosorangicin A (1) and neosorangioside A (2), from Sorangium cellulosum strain Soce439, elucidated their molecular structures, thereby revealing significant structural variation in comparison to sorangicin, and describe their biosynthetic pathway. Neosorangicin A (1) exhibited strong activity against various Gram-positive bacteria, including potent effects against Mycobacterium tuberculosis and enhanced efficacy on intracellular Staphylococcus aureus. In a murine wound infection model, a head-to-head comparison of neosorangicin A (1) and sorangicin A (3) provided useful insights into how the altered physicochemical properties, arising from the shortened side chain and the lack of the free carboxylic acid of neosorangicin A, influence the in vivo efficacy of sorangicin derivatives.